EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)LeserbriefOpen Access · CC BY 4.0

Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency

Kevin H M Kuo iD, Rachael F Grace iD, Eduard J van Beers, Wilma Barcellini iD, Andreas Glenthøj iD, Susanne Holzhauer, Vanessa Beynon, Susan Morris, Junlong Li, Erin Zagadailov, Parija Patel, Hanny Al-Samkari iD

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27312 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Kevin H M Kuo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Pyruvate Kinase, Pyruvate Metabolism, Inborn Errors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agios Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresPyruvate KinasePyruvate Metabolism, Inborn ErrorsHumansAdultMaleFemaleMiddle AgedAnemia, Hemolytic, Congenital NonspherocyticTreatment Outcome

Substanzen

Pyruvate Kinase

Autor:innen und Institutionen

  • Division of Hematology, University of Toronto, Toronto, Ontario, Canada.
  • Dana-Farber/Boston Children's Cancer and Blood Disorder Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
  • Department of Pediatric Hematology and Oncology, Charité University Medicine, Berlin, Germany.

ORCID-Profile: Kevin H M Kuo, Rachael F Grace, Wilma Barcellini, Andreas Glenthøj, Hanny Al-Samkari

Förderung

  • Agios Pharmaceuticals

Zitieren

APA

Kuo, K. H. M., Grace, R. F., van Beers, E. J., Barcellini, W., Glenthøj, A., Holzhauer, S., Beynon, V., Morris, S., Li, J., Zagadailov, E., Patel, P., & Al-Samkari, H. (2024). Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency. American Journal of Hematology. https://doi.org/10.1002/ajh.27312

Vancouver

Kuo KHM, Grace RF, van Beers EJ, Barcellini W, Glenthøj A, Holzhauer S, et al. Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency. American Journal of Hematology. 2024. doi:10.1002/ajh.27312

BibTeX
@article{Kuo2024,
  author = {Kuo, Kevin H M and Grace, Rachael F and van Beers, Eduard J and Barcellini, Wilma and Glenthøj, Andreas and Holzhauer, Susanne and Beynon, Vanessa and Morris, Susan and Li, Junlong and Zagadailov, Erin and Patel, Parija and Al-Samkari, Hanny},
  title = {Clinically meaningful improvements in patient‐reported outcomes in mitapivat‐treated patients with pyruvate kinase deficiency},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27312}
}
Kostenlos starten →